Intrarosa (prasterone) is not strongly linked to weight gain in clinical trials. Weight gain was not listed among the common side effects in four placebo-controlled studies involving over 1,100 women, and the only adverse reaction reported by more than 2% of participants was vaginal discharge. Still, some women notice changes on the scale after starting Intrarosa, and there are plausible biological reasons worth understanding.
How Intrarosa Works Inside the Body
Intrarosa is a vaginal insert containing prasterone, a synthetic version of DHEA, a hormone your body naturally produces. DHEA itself has no direct hormonal activity. Once inside vaginal cells, enzymes convert it into four active sex hormones: estradiol, estrone, testosterone, and dihydrotestosterone (DHT). These hormones act on receptors within those same cells to restore tissue health, then get broken down into inactive byproducts before leaving the cell.
The manufacturer describes this as “intracrinology,” the idea that the hormones are made and used entirely within the local tissue, never reaching the bloodstream in meaningful amounts. The FDA approved the drug on this basis. However, the European Medicines Agency took a closer look at the pharmacokinetic data and reached a more nuanced conclusion: blood levels of DHEA, estrone, and testosterone did show statistically significant increases compared to baseline and placebo. The increases stayed within the normal postmenopausal range, but they were real and measurable.
This distinction matters. A small but genuine rise in circulating hormones, even within normal limits, could theoretically influence metabolism, fluid balance, or fat distribution over time.
Why Some Women Notice Weight Changes
There are a few possible explanations for weight gain while using Intrarosa, even though clinical trials didn’t flag it as a common side effect.
The first is mild fluid retention. Androgens like testosterone and DHT, even at low levels, can promote water and sodium retention. The FDA’s medical review of Intrarosa acknowledged that anabolic-androgenic steroids are generally associated with fluid retention and acne, though reviewers did not attribute those effects to the 6.5 mg vaginal dose specifically. A small shift in fluid balance could show up as a pound or two on the scale without reflecting actual fat gain.
The second possibility involves subtle hormonal shifts in metabolism. Estrogens and androgens both influence where your body stores fat and how efficiently it burns calories. Even modest changes in circulating levels could, in theory, nudge body composition over weeks or months. This effect would be difficult to detect in a 12-week clinical trial, which is the duration most Intrarosa studies used.
The third, and arguably most likely, explanation is timing. Intrarosa is prescribed to postmenopausal women, a group already experiencing significant metabolic changes that have nothing to do with the medication.
Menopause Itself Drives Weight Gain
Most women gain weight during and after menopause regardless of whether they use any medication. Several overlapping factors are responsible. Muscle mass naturally declines with age, and since muscle burns more calories at rest than fat does, your baseline metabolic rate drops. Physical activity levels also tend to decrease. Genetic factors influence whether extra weight settles around the abdomen, which is the pattern most common after menopause. Even sleep disruption, which is extremely common during this stage of life, increases snacking and overall calorie intake.
These changes happen gradually and often coincide with starting a new medication like Intrarosa. It’s natural to attribute the weight change to the new pill or insert, but the timeline overlap can be misleading. A woman who gains three or four pounds over the first few months of using Intrarosa may well have gained the same weight without it.
What the Clinical Data Actually Shows
Across four placebo-controlled trials with 665 women taking Intrarosa and 464 taking a placebo, the only treatment-related side effect exceeding 2% was vaginal discharge, reported by about 6% of women on the drug versus 4% on placebo. Weight gain did not appear as a statistically significant adverse event in these studies or in a separate 12-month open-label safety trial. The FDA’s medical review concluded that no major safety issues were identified with the 6.5 mg vaginal insert.
That said, clinical trials have limitations. They’re relatively short, they use group averages that can mask individual responses, and participants who gain a small amount of weight may not report it as a side effect. The absence of weight gain in trial data doesn’t mean no individual will experience it. It means it wasn’t common enough or large enough to show up as a pattern.
How to Tell If Intrarosa Is the Cause
If you’ve gained weight since starting Intrarosa, a practical approach is to track your weight for a few weeks while keeping your diet and activity level consistent. Fluid-related weight gain from hormonal changes tends to appear quickly (within the first few weeks) and may fluctuate day to day. Fat gain from metabolic changes is slower and steadier.
You can also pay attention to where the weight appears. Fluid retention often shows up as puffiness in the hands, ankles, or face. Abdominal fat accumulation is more characteristic of the metabolic shifts of menopause itself. If you notice rapid or significant weight gain (more than five pounds in a month without a clear dietary explanation), that’s worth discussing with your prescriber, not because Intrarosa is dangerous, but because it may signal something else going on.
For most women, the small systemic hormone increases from Intrarosa are unlikely to produce noticeable weight gain on their own. The more common culprit is the broader metabolic landscape of postmenopause, which Intrarosa happens to coincide with.